[go: up one dir, main page]

MX2010009766A - Ensayo de proteasa. - Google Patents

Ensayo de proteasa.

Info

Publication number
MX2010009766A
MX2010009766A MX2010009766A MX2010009766A MX2010009766A MX 2010009766 A MX2010009766 A MX 2010009766A MX 2010009766 A MX2010009766 A MX 2010009766A MX 2010009766 A MX2010009766 A MX 2010009766A MX 2010009766 A MX2010009766 A MX 2010009766A
Authority
MX
Mexico
Prior art keywords
protease
protease assay
assay
target protease
cancerous
Prior art date
Application number
MX2010009766A
Other languages
English (en)
Inventor
Stefan H Bossmann
Deryl L Troyer
Matthew T Basel
Original Assignee
Univ Kansas State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas State filed Critical Univ Kansas State
Publication of MX2010009766A publication Critical patent/MX2010009766A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/774—Exhibiting three-dimensional carrier confinement, e.g. quantum dots
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La presente invención proporciona un reactivo de diagnóstico o ensayo para evaluar la actividad de una proteasa in vivo o in vitro y métodos para detectar la presencia de una célula cancerosa o precancerosa. Los ensayos están comprendidos de dos partículas enlazadas por medio de un enlace de oligopéptido que comprende una secuencia de consenso específica para la proteasa objetivo. La escisión de la secuencia por la proteasa objetivo puede ser detectada visualmente o usando varios sensores, y los resultados de diagnóstico pueden estar correlacionados con prognosis de cáncer.
MX2010009766A 2008-03-03 2009-03-03 Ensayo de proteasa. MX2010009766A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6789108P 2008-03-03 2008-03-03
PCT/US2009/035875 WO2009111470A2 (en) 2008-03-03 2009-03-03 Protease assay

Publications (1)

Publication Number Publication Date
MX2010009766A true MX2010009766A (es) 2010-09-28

Family

ID=41056602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009766A MX2010009766A (es) 2008-03-03 2009-03-03 Ensayo de proteasa.

Country Status (7)

Country Link
US (3) US8969027B2 (es)
EP (1) EP2260108B1 (es)
JP (1) JP2011517934A (es)
AU (1) AU2009221976B2 (es)
CA (1) CA2717563C (es)
MX (1) MX2010009766A (es)
WO (1) WO2009111470A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979409B1 (en) 1997-02-20 2006-12-27 The Regents of the University of California Plasmon resonant particles, methods and apparatus
KR100857770B1 (ko) * 2007-04-11 2008-09-09 한국과학기술연구원 단백질 분해효소 검출 및 생체 내 영상화를 위한 금속 나노입자 및 그것의 용도
US20120003662A1 (en) 2007-10-18 2012-01-05 University Of Medicine And Dentistry Of New Jersey Methods and Kits for Detecting Mastitis
EP2260108B1 (en) * 2008-03-03 2014-09-17 Kansas State University Research Foundation Protease assay
EP4032538A3 (en) 2009-03-02 2022-10-26 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
EP2451839B1 (en) * 2009-07-10 2020-04-22 Ablynx N.V. Method for the production of variable domains
EP2473620A4 (en) * 2009-09-02 2013-06-05 Univ Kansas State MRI AND OPTICAL ASSAYS FOR PROTEASES
EP2483680A4 (en) * 2009-09-30 2014-01-01 Quantapore Inc ULTRASOUND SEQUENCING OF BIOLOGICAL POLYMERS WITH THE HELP OF A MARKED NANOPORE
JP5853703B2 (ja) * 2010-02-02 2016-02-09 コニカミノルタ株式会社 アナライト検出プローブ、アナライト検出試薬およびこれを用いたアナライトの検出方法
EP2547733A1 (en) * 2010-03-17 2013-01-23 Nanologica AB Enhanced folic acid fluorescent material, multifluorescent porous compositions of matter and potential applications thereof
EP2372347A1 (en) * 2010-03-26 2011-10-05 Institut Pasteur Method to increase the number of detectable photons during the imaging of a biological marker
CN102269758B (zh) * 2010-06-04 2013-11-20 国家纳米科学中心 可视化检测抗原抗体反应的方法、试剂盒及其应用
WO2012050896A2 (en) 2010-09-29 2012-04-19 Kansas State University Research Foundation Protease selective supramolecular assemblies
EP2646059A4 (en) * 2010-12-01 2016-07-27 Methodist Hospital System PROTEASE-DERIVABLE POLYPEPTIDES AND USES THEREOF
CA2846852C (en) 2011-08-30 2021-01-12 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
US10493168B2 (en) * 2012-02-27 2019-12-03 Oxygen Enterprises, Ltd Phosphorescent meso-unsubstituted metallo-porphyrin probe molecules for measuring oxygen and imaging methods
EA201491551A1 (ru) * 2012-02-27 2015-02-27 Сергей Виноградов Улучшенные фосфоресцентные молекулы для измерения содержания кислорода и способы визуализации
DE102012101744B4 (de) * 2012-03-01 2021-06-24 BAM Bundesanstalt für Materialforschung und -prüfung Verfahren zur Bestimmung der Helligkeit eines lumineszenten Teilchens
CN102608092B (zh) * 2012-03-28 2014-03-12 哈尔滨工业大学 高灵敏度的铜离子检测用荧光生物传感器及其检测方法
JP6195339B2 (ja) 2012-07-10 2017-09-13 キヤノン株式会社 粒子及び前記粒子を有する光音響用造影剤
CN103149185B (zh) * 2013-02-05 2014-12-10 苏州大学 一种新型高效的蛋白酶活性检测方法
US9439976B2 (en) 2013-02-13 2016-09-13 The Methodist Hospital System Compositions and methods for using cathepsin E cleavable substrates
PL230602B1 (pl) 2013-04-04 2018-11-30 Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk Kwas (E)-3-arylo-3-oksoprop-1-enylo-2-fosfonowy i jego pochodne, sposob ich wytwarzania oraz ich zastosowanie
PL223918B1 (pl) 2013-05-28 2016-11-30 Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk 3-Arylo-2-fosforylo podstawione 1-indanony i sposób ich wytwarzania
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
US20160175254A1 (en) * 2013-08-07 2016-06-23 University Of Zululand The synthesis of core-shell metal-semiconductor nanomaterials
TWI500769B (zh) * 2013-12-30 2015-09-21 Univ Nat Chiao Tung 用於檢測蛋白酶活性的奈米粒子螢光探針及其應用
US9272268B2 (en) * 2014-04-01 2016-03-01 Ut-Battelle, Llc Catalysts for low temperature oxidation
CN105021819B (zh) * 2014-04-28 2017-05-03 中国科学院苏州纳米技术与纳米仿生研究所 荧光纳米磁性粒子‑多肽底物复合体及其制备方法
CN104020287B (zh) * 2014-06-24 2015-09-16 朱高红 一种含有放射性核素的血清特异活性蛋白酶检测纳米试剂盒
WO2016018798A1 (en) * 2014-07-28 2016-02-04 Kansas State University Research Foundation Nanosensors for detecting enzymatic activity in dairy production
US10024817B2 (en) 2014-10-17 2018-07-17 Pelogenix, Llc Method for detecting proteases and active infection in biological fluids and tissues
JP6463166B2 (ja) * 2015-02-20 2019-01-30 日鉄ケミカル＆マテリアル株式会社 金属複合体粒子及びその製造方法
US10376599B2 (en) 2015-03-19 2019-08-13 Kansas State University Research Foundation Nanoplatforms for arginase, indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase detection by posttranslational modification
CN104865299B (zh) * 2015-05-16 2016-04-20 济南大学 一种纳米金钯/3-氨丙基三乙氧基硅烷化三氧化二锰的psa传感器制备方法及应用
WO2017165800A2 (en) * 2016-03-25 2017-09-28 The Board Of Regents Of The University Of Texas System Nanosensors and methods for detection of biological markers
EP3440013A4 (en) * 2016-04-08 2021-03-17 Massachusetts Institute of Technology METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES
CA3022928A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
CN106404728B (zh) * 2016-08-24 2018-11-09 江苏大学 多种转基因元件同时快速检测的方法
EP3519583A4 (en) * 2016-09-28 2020-06-03 Georgia Tech Research Corporation METHOD AND COMPOSITIONS FOR NON-INVASIVE DETECTION OF ORGAN TRANSPLANT REJECTION
WO2018094213A1 (en) 2016-11-18 2018-05-24 Kansas State University Research Foundation Microfluidics-based nanobiosensors and devices
WO2018187688A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
WO2019236992A1 (en) * 2018-06-08 2019-12-12 Glympse Bio, Inc. Activity sensor design
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
US11732009B2 (en) 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
WO2020160232A1 (en) * 2019-02-01 2020-08-06 Glympse Bio, Inc. Detecting architectural remodelling in cells extracellular matrix, and the tissue microenvironment
WO2020191416A2 (en) 2019-02-28 2020-09-24 Georgia Tech Research Corporation Compositions and methods for logic-gated profiling of biologic activity
US12440582B2 (en) * 2019-06-17 2025-10-14 Board Of Regents, The University Of Texas System Biothiol-activatable probe and method of use
CA3144839A1 (en) * 2019-06-24 2020-12-30 Urteste S.A. Diagnostic marker for pancreatic cancer
US12091776B2 (en) 2019-06-27 2024-09-17 The John Hopkins University Protease activity profiling via programmable phage display of comprehensive proteome-scale peptide libraries
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
WO2022147179A1 (en) * 2020-12-30 2022-07-07 Kansas State University Research Foundation Nanosensors for rapid identification of lung conditions
CN114981205A (zh) 2020-12-30 2022-08-30 鹰眼生物有限公司 用于生物标志物检测的基于原始石墨烯的生物传感器以及相关核心颗粒、材料组合物方法和系统
JP2024517871A (ja) * 2021-05-07 2024-04-23 ザ・ユニバーシティ・オブ・シカゴ プロテアーゼ活性化治療剤を含む組成物および方法
WO2024010609A1 (en) 2022-07-06 2024-01-11 Hawkeye Bio, Limited Pristine graphene based biosensor for biomarker detection and related core particles, materials compositions methods and systems
CN115932266B (zh) * 2022-12-01 2024-07-19 重庆医科大学 用于非小细胞肺癌cyfra21-1检测的电致化学发光免疫传感器及检测方法
CN116354970B (zh) * 2023-03-28 2024-06-18 大连理工大学 一种卟啉类一氧化碳前药的制备方法及气体-声动力联合治疗应用
CN117723526B (zh) * 2024-02-04 2024-04-12 云南伦扬科技有限公司 一种单原子纳米酶基荧光探针快速检测草甘膦和镉方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1052293B1 (en) * 1999-05-12 2003-12-17 Hamamatsu Photonics K.K. Nucleic acid detection in cytoplasm
AT410601B (de) * 2000-12-29 2003-06-25 Hoffmann La Roche Sensor zur lumineszenz-optischen bestimmung eines analyten sowie reagens, das nach dem fret-prinzip arbeitet
US20060286379A1 (en) * 2002-08-13 2006-12-21 Yong Gao Magnetic nanoparticle supports
US20140336514A1 (en) * 2005-08-05 2014-11-13 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
US8557971B2 (en) 2006-03-17 2013-10-15 Aarhus Universitet Chimeric viral envelopes
EP2260108B1 (en) * 2008-03-03 2014-09-17 Kansas State University Research Foundation Protease assay
EP2473620A4 (en) * 2009-09-02 2013-06-05 Univ Kansas State MRI AND OPTICAL ASSAYS FOR PROTEASES
WO2012050896A2 (en) * 2010-09-29 2012-04-19 Kansas State University Research Foundation Protease selective supramolecular assemblies

Also Published As

Publication number Publication date
AU2009221976A1 (en) 2009-09-11
US9682155B2 (en) 2017-06-20
EP2260108A4 (en) 2011-09-28
US20110014125A1 (en) 2011-01-20
WO2009111470A2 (en) 2009-09-11
AU2009221976B2 (en) 2014-02-27
US20150132785A1 (en) 2015-05-14
EP2260108A2 (en) 2010-12-15
CA2717563C (en) 2017-02-28
EP2260108B1 (en) 2014-09-17
CA2717563A1 (en) 2009-09-11
JP2011517934A (ja) 2011-06-23
US9731034B2 (en) 2017-08-15
US20150132230A1 (en) 2015-05-14
US8969027B2 (en) 2015-03-03
WO2009111470A3 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
MX2010009766A (es) Ensayo de proteasa.
EP4235181A3 (en) Biomarker detection process and assay of neurological condition
WO2007008759A3 (en) Methods for detecting and confirming minimal disease in a cancer patient
WO2011028698A3 (en) Mri and optical assays for proteases
WO2011119934A3 (en) Methods and materials for detecting colorectal neoplasm
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2007089911A3 (en) Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
WO2011022093A3 (en) Methods and devices for detecting the presence of an analyte in a sample
MX338883B (es) Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
WO2009024691A3 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2011053790A3 (en) Assay of closely linked genetic targets in fetal diagnosis
WO2013033629A3 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
WO2008094902A3 (en) Compositions and methods for the detection of a nucleic acid using a cleavage reaction
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
WO2009017861A3 (en) Analyte detection using autocatalytic chain reactions
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
EP1943353A4 (en) HEALTH CONDITION TEST
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012012802A3 (en) Neoepitope detection of disease using protein arrays
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
NZ592994A (en) Diagnostic test for Streptococcus equi comprising assessing the presence or absence of the S. equi eqbE gene